---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007037"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T06:57:06.571463+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical reports Q4 net loss of $9.7M; Phase 2b wet AMD trial on track for Q2 2023

## Summary
- Q4 net loss $9.7M ($0.16/share) vs net income $18.7M ($0.31/share) in Q4 2021 on lower license revenue.
- Full-year 2022 net loss $32.9M ($0.55/share) vs net income $376K ($0.01/share) in 2021.
- Cash $48.3M at Dec 31, 2022; runway into Q2 2024.
- Phase 2b ODYSSEY trial of CLS-AX in wet AMD to start Q2 2023; comparator arm adjusted to on-label aflibercept per FDA draft guidance.
- Bausch + Lomb trained over 1,000 retinal physicians on SCS Microinjector for XIPERE.

## SEC filing metadata
- accession: 0000950170-23-007037
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/0000950170-23-007037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/clsd-20230309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007037
- JSON: https://secwatch.observer/filing/0000950170-23-007037.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007037.txt

## Key facts
- Earnings Releases
  Clearside Biomedical, Inc. reported Year ended December 31, 2022 results: revenue $1.3 million, net income Net loss of $32.9 million, EPS $0.55 per share.
  - Period: Year ended December 31, 2022
  - Revenue: $1.3 million
  - Net income: Net loss of $32.9 million
  - EPS: $0.55 per share
  - Result: reported results
  source text: Clearside’s license and other revenue for the year ended December 31, 2022, was $1.3 million, compared to $29.6 million for the year ended December 31, 2021. The $28.2 million decrease was primarily attributable to one-time milestone payments received from XIPERE licensing partners in 2021. Cost of goods sold for the year ended December 31, 2022, was $204,000, compared to $0 for the year ended December 31, 2021. This increase was related to sales of Clearside’s SCS Microinjector. Research and development expenses for the year ended December 31, 2022, were $19.6 million, compared to $18.5 million for the year ended December 31, 2021. The $1.1 million increase was primarily attributable to CLS-AX program costs. General and administrative expenses for the year ended December 31, 2022, were $11.8 million, compared to $11.7 million for the year ended December 31, 2021. Net loss for the year ended December 31, 2022, was $32.9 million, or $0.55 per share of common stock, compared to net incom
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/0000950170-23-007037-index.htm
- Earnings Releases
  Clearside Biomedical, Inc. reported Fourth quarter 2022 results: revenue $330,000, net income Net loss of $9.7 million, EPS $0.16 per share.
  - Period: Fourth quarter 2022
  - Revenue: $330,000
  - Net income: Net loss of $9.7 million
  - EPS: $0.16 per share
  - Result: reported results
  source text: Clearside’s license and other revenue for the fourth quarter of 2022 was $330,000, compared to $25.7 million for the fourth quarter of 2021. The $25.4 million decrease was primarily attributable to one-time milestone payments received from XIPERE licensing partners in the fourth quarter of 2021. Cost of goods sold for the fourth quarter of 2022 was $204,000, compared to $0 for the fourth quarter of 2021. This increase was related to sales of Clearside’s SCS Microinjector. Research and development expenses for the fourth quarter of 2022 were $5.0 million, compared to $3.8 million for the fourth quarter of 2021. The $1.2 million increase was primarily attributable to preclinical research program costs. General and administrative expenses for the fourth quarter of 2022 were $3.2 million, compared to $3.1 million for the fourth quarter of 2021. Net loss for the fourth quarter of 2022 was $9.7 million, or $0.16 per share of common stock, compared to net income of $18.7 million, or $0.31 per
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023007037/0000950170-23-007037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.